PTAB invalidates key claims of Brigham and Women’s patent

The PTAB invalidated central claims of U.S. Patent No. 11,435,360, striking down the sole independent claim related to nanoparticle biomolecule coronas, a win for PreOmics/Biognosys (Bruker subsidiaries) and a setback for the patent holder/licensor Seer. Bruker (market cap $5.44B) reported Q4 2025 EPS of $0.59 vs $0.65 consensus (miss) but revenue of $977.2M vs $959.08M consensus (beat); shares are down ~27% YTD to $35.69. The company announced new spatial biology platforms (including PaintScape) with commercial shipments planned this spring, a board change (Dr. Cynthia M. Friend will not stand for re-election) and a declared quarterly dividend. Microsoft’s GigaTIME AI and concerns about demand for spatial proteomics were cited as headwinds that have pressured sector stocks such as Bruker and 10x Genomics.

Analysis

When an IP-based wedge erodes, instrument and consumable vendors are best positioned to convert that into revenue because they already own distribution, service, and recurring-revenue relationships. Consumables typically carry 40–60% gross margins and a high attach rate; an incremental 1–2% penetration into installed mass-spec labs can translate into low-double-digit revenue tailwinds for a $5–10B vendor over 12–24 months.

The next 9–18 months are decisive: appellate outcomes and any licensing settlements will set durable legal boundaries, but commercial share shifts happen much faster — within 2–8 quarters — as labs test alternative workflows. Look for early read-throughs in order backlog, consumables ASPs, and software subscription churn; these metrics will move faster than headline revenue numbers and give leading indicators of share capture.

Principal risks are binary legal reversals and rapid product substitution from AI-platform entrants that can lower willingness to pay for specialized spatial-proteomics platforms over a 6–24 month horizon. A balanced trade extracts upside from incumbents’ recurring revenues while hedging against a data/AI-led substitution where users prefer cheaper, model-driven inference over instrument-led measurements.

Key Decisions for Investors

• Pair trade (12 months): Long BRKR-equivalent exposure (buy shares or 1.0x notional of 12-month calls) / Short SEER (borrow and short shares or buy 6-month puts). Thesis: capture consumables/subscription rerate in the incumbent while shorting the exposed pure-play whose exit options narrow. Target: +30% on long leg vs -40% on short leg; initial position size 1–2% NAV, stop-loss if long leg falls 12% or short leg rallies 25%.
• Options hedge (6–12 months): Buy BRKR 12-month LEAP calls (delta ~0.40) sized at 0.5–1% NAV to maintain asymmetric upside with defined downside. Use premium as max loss; target 2.5x payoff if instrument/consumables attach rates accelerate in next two quarters.
• Event-driven short (3–6 months): Buy SEER 3–6 month puts or short shares around any relief rallies tied to press releases. Risk/reward skewed: legal appeals or pivot announcements can spike volatility—limit to 0.5% NAV and use tight time decay management (close 30–40% into profits).
• Sector pair hedge (9–18 months): Long a diversified, cash-generative instrument/consumables leader (BRKR-like) and short a pure spatial-proteomics exposure (TXG-like) to isolate product-substitution risk from AI entrants. Target portfolio tilt +5% active weight to longs vs shorts; rebalance on quarterly attach-rate prints.
• Risk monitor & triggers: Reduce net exposure if an appellate ruling is scheduled within 60 days (legal binary) or if MSFT-equivalent AI deployments announce broad lab partnerships — both events increase tail risk and should prompt cutting positions by at least 50%.